

PANBIO™ COVID-19 ANTIGEN TESTS AND EMERGING VARIANTS

No Predicted Impact of the Delta Variant on Panbio™ COVID-19 Ag Rapid Test Device and Panbio™ COVID-19 Antigen Self-Test

Abbott is continuously monitoring the global SARS-CoV-2 situation through complex processes overseen by the Abbott Pandemic Defense Coalition.^{1,2} As emerging variants are identified, sequence and in silico analyses are conducted to evaluate potential impact of these mutations to our tests.



THERE IS NO PREDICTED IMPACTED ON PANBIO™ COVID-19 ANTIGEN TEST PERFORMANCE BY ANY OF THESE VARIANTS ANALYZED AS OF JUNE 28, 2021, INCLUDING THE DELTA VARIANT:

COUNTRY FIRST DETECTED	LINEAGE	WHO NOMENCLATURE	ADDITIONAL NOMENCLATURE	COUNTRY FIRST DETECTED	LINEAGE	WHO NOMENCLATURE	ADDITIONAL NOMENCLATURE
BRAZIL	P.2	ZETA	VUI-202101/01, VUI-21JAN-01, 20J	INDIA	B.1.618	NOT DESIGNATED	NONE TO DATE
BRAZIL	P.1.1	GAMMA	G/478K.V1, 21A	INDIA	AY.1	DELTA	DELTA PLUS
BRAZIL	P.1.2	GAMMA	G/478K.V1, 21A	INDIA	AY.2	DELTA	CLADE G/478K.V1; 21A/S:417N
CALIFORNIA, USA	B.1.427	EPSILON	20C/S:452R; CLADE GH/452R.V1; CAL.20C/L452R	INDIA	AY.3	DELTA	CLADE G/478K.V1; 21A/S:417N
CALIFORNIA, USA	B.1.429	EPSILON	20C/S:452R; CLADE GH/452R.V1; CAL.20C/L452R	INDONESIA	B.1.466.2	NOT DESIGNATED	CLADE GH
COLUMBIA	B.1.621	NOT DESIGNATED	NONE TO DATE	JAPAN AND USA	R.1	NOT DESIGNATED	NONE TO DATE
ENGLAND, UK	A.23.1+E484K	NOT DESIGNATED	VUI-21FEB-01, VUI-202102/01	JAPAN EX MANAUS, BRAZIL	P.1	GAMMA	B1.1.28.1, VOC-202101/02, VOC-21JAN-02, 20J/501Y.V3
ENGLAND, UK	AV.1	NOT DESIGNATED	VUI-21MAY-01	MEXICO	B.1.1.519	NOT DESIGNATED	CLADE GR; 20B
ENGLAND, UK	B.1.1.7	ALPHA	VOC-202012/01, VOC-20DEC-01, VUI-202012/01; VUI-202012/01; CLADE GR; 20I/501Y.V1	NEW YORK, USA	B.1.526	IOTA	20C/S:484K; CLADE GH
ENGLAND, UK	B.1.1.7 WITH E484K	NOT DESIGNATED	VOC-21FEB-02; VOC-202102/02	NEW YORK, USA	B.1.526.1	NOT DESIGNATED	20C
ENGLAND, UK	B.1.1.318	NOT DESIGNATED	VUI-21FEB-04, VUI-202102/04	NEW YORK, USA	B.1.526.2	NOT DESIGNATED	NONE TO DATE
ENGLAND, UK, NIGERIA	B.1.525	ETA	VUI-21FEB-03, VUI-202102/03; 20A/S:484K; CLADE G/484K.V3	PERU	C.37	LAMBDA	20D, GR/452Q.V1
FRANCE	B.1.616	NOT DESIGNATED	20C; CLADE GH	PHILLIPPINES	P.3	THETA	VUI-21MAR-02
INDIA	B.1.617.1	KAPPA	VUI-21APR-01; 20A/S:154K	RUSSIA	AT.1	NOT DESIGNATED	VUI-21MAY-01
INDIA	B.1.617.2	DELTA	VOC-21APR-02; 20A/S:478K	SOUTH AFRICA	B.1.351	BETA	VOC-202012/02, VOC-20DEC-02, 20H/501Y.V2, 501Y.V2, CLADE GH/501Y.V1
INDIA	B.1.617.3	NOT DESIGNATED	VUI-21APR-03; 20A				
INDIA	B.1.618	NOT DESIGNATED	NONE TO DATE				
INDIA	B.1.617.3	NOT DESIGNATED	VUI-21APR-03; 20A				

COUNTRY FIRST DETECTED	LINEAGE	WHO NOMENCLATURE	ADDITIONAL NOMENCLATURE
SOUTH AFRICA	B.1.351.2	BETA	CLADE GH/501Y.V2; 20H(V2)/S:L18F
SOUTH AFRICA	B.1.351.3	BETA	CLADE GH/501Y.V2; 20H(V2)/S:L18F
NOT CONFIRMED	A.27	NOT DESIGNATED	NONE TO DATE
NOT CONFIRMED	B.1.1.523	NOT DESIGNATED	CLADE GR
NOT CONFIRMED	B.1.214.2	NOT DESIGNATED	CLADE G
NOT CONFIRMED	B.1.429.1	NOT DESIGNATED	NONE TO DATE

Abbott will continue to publish evaluations as emerging variants continue to arise.



Product not available in all countries. The Panbio™ COVID-19 Rapid Test Device is not available for use in New Zealand without authorisation. The Panbio™ COVID-19 Rapid Self-Test is not available for sale in Australia and New Zealand. Please check with Abbott for availability in your country.

- <https://abbott.mediaroom.com/2021-03-11-Abbott-Announces-its-Pandemic-Defense-Coalition-A-Global-Network-of-Expert-Collaborators-Designed-To-Help-Prevent-Future-Pandemics-Currently-Searching-for-COVID-19-Variants>
- <https://www.abbott.com/corpnnewsroom/products-and-innovation/how-we-track-covid-19-variants.html>

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. COL-06920-02 09/21

